TITLE:
Fulvestrant (FASLODEX) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer

CONDITION:
Breast Cancer

INTERVENTION:
Fulvestrant

SUMMARY:

      The purpose of this study is to evaluate fulvestrant in the preliminary stage of breast
      cancer treatment and assess the relationship between dose, exposure, degree of reduction in
      tumor markers, and efficacy in postmenopausal women with estrogen receptor positive disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  Postmenopausal women defined as women who have stopped having menstrual periods

          -  Written informed consent to participate in the trial

          -  Biopsy confirmation of invasive breast cancer

          -  Evidence of hormone sensitivity

          -  Willingness to undergo biopsies

        Exclusion Criteria:

          -  Any previous treatment for breast cancer

          -  Unwillingness to stop taking any drug known to affect sex hormonal status or a
             patient in which it would be inappropriate to stop.

          -  Any severe concurrent condition that would preclude surgery or that would jeopardize
             compliance with the study, e.g., uncontrolled cardiac disease or uncontrolled
             diabetes mellitus

          -  The presence of more than one primary tumor

          -  History of hypersensitivity to castor oil

          -  History of known bleeding disorders
      
